Mirati Therapeutics, Inc. (MRTX) News

Mirati Therapeutics, Inc. (MRTX): $58.70

0.10 (-0.17%)

POWR Rating

Component Grades








Add MRTX to Watchlist
Sign Up

Industry: Biotech




#304 of 359

in industry

Filter MRTX News Items

MRTX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

MRTX News Highlights

  • MRTX's 30 day story count now stands at 4.
  • Over the past 15 days, the trend for MRTX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • AMGN and LUNG are the most mentioned tickers in articles about MRTX.

Latest MRTX News From Around the Web

Below are the latest news stories about MIRATI THERAPEUTICS INC that investors may wish to consider to help them evaluate MRTX as an investment opportunity.

FDA Rejects Amgen's (AMGN) NDA Seeking Full Nod for Lumakras

Per the FDA, Amgen (AMGN) will need to complete an additional confirmatory study on Lumakras in certain lung cancer patients before February 2028 to secure full approval.

Yahoo | December 27, 2023

Mirati Therapeutics Inc EVP & Chief Scientific Officer Jamie Christensen Sells 2,387 Shares

On December 18, 2023, Jamie Christensen, EVP & Chief Scientific Officer of Mirati Therapeutics Inc (NASDAQ:MRTX), executed a sale of 2,387 shares in the company.

Yahoo | December 20, 2023

Insider Sell Alert: EVP Benjamin Hickey Sells Shares of Mirati Therapeutics Inc (MRTX)

In a recent transaction on December 13, 2023, Benjamin Hickey, the Executive Vice President and Chief Commercial Officer of Mirati Therapeutics Inc (NASDAQ:MRTX), sold 2,220 shares of the company.

Yahoo | December 15, 2023

Billionaire Joe Lewis Keeps Trading Stocks Behind US Insider-Trading Charges

(Bloomberg) -- Joe Lewis, the British billionaire behind one of the world’s biggest investing fortunes, continues to buy and sell stocks at the center of US insider-trading allegations against him.Most Read from BloombergJPMorgan Is in a Fight Over Its Client’s Lost $50 Million FortuneGoldman Trader Paid $100 Million Since 2020 Is Stepping DownArgentina’s Milei Devalues Peso by 54% in First Batch of Shock MeasuresNetflix Posts Viewer Data on Every Show, Film for First TimeRaimondo Vows ‘Stronges

Yahoo | December 12, 2023

3 Resilient Stocks with Massive Potential to Boost Your Wealth

These three stocks with massive potential can make patient investors fabuslously wealthy as they come roaring back to life.

Rich Duprey on InvestorPlace | November 26, 2023

3 Biotech Stocks That Could Boom or Bust by 2025

Biotech stocks are popular with investors because they sometimes provide tremendous rewards.

Will Ashworth on InvestorPlace | November 16, 2023

UPDATE 1-Mirati's lung cancer drug gets EU's regulatory backing

Mirati Therapeutics said on Friday the European medicines regulator's panel has recommended approval of its treatment for a type of lung cancer. The European Medicine Agency's committee backed Krazati following a re-examination of the drug the panel had declined to back for authorization in July, saying the requirements for conditional support were not fulfilled, which Mirati had disagreed with. Krazati received the U.S. Food and Drug Administration's accelerated approval last year and also the UK health regulator's authorization earlier this month.

Yahoo | November 10, 2023

Mirati Therapeutics Receives Positive Opinion from CHMP for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation Following a Re-Examination Procedure

Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced that following a re-examination procedure, the Company has received a positive opinion from the European Medicine Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) on KRAZATI® (adagrasib) as a targeted treatment option for adult patients with KRASG12C -mutated advanced non-small cell lung cancer (NSCLC) and disease progression after at least one prior systemic therapy.

Yahoo | November 10, 2023

Mirati's (MRTX) Q3 Loss Narrows, Sales Miss Expectations

Mirati (MRTX) posts mixed third-quarter results as the bottom line exceeds estimates while the top line misses.

Yahoo | November 7, 2023

Paramount slashed 2 notches to sell; Ameresco in free fall: 5 big analyst cuts

BofA on Monday downgraded media conglomerate Paramount Global (NASDAQ:PARA) by two notches - to Underperform from Buy - with a price target of $9.00 (from $32.00).

Yahoo | November 7, 2023

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!